Charles River Laboratories International Company Profile (NYSE:CRL)

About Charles River Laboratories International

Charles River Laboratories International logoCharles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NYSE
  • Symbol: CRL
  • CUSIP: 15986410
Key Metrics:
  • Previous Close: $89.54
  • 50 Day Moving Average: $82.61
  • 200 Day Moving Average: $79.44
  • 52-Week Range: $67.20 - $89.73
  • Trailing P/E Ratio: 27.76
  • Foreward P/E Ratio: 15.88
  • P/E Growth: 1.52
  • Market Cap: $4.24B
  • Outstanding Shares: 47,372,000
  • Beta: 0.99
Profitability:
  • Net Margins: 9.05%
  • Return on Equity: 25.75%
  • Return on Assets: 8.65%
Debt:
  • Debt-to-Equity Ratio: 1.41%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.35%
Additional Links:
Companies Related to Charles River Laboratories International:

Analyst Ratings

Consensus Ratings for Charles River Laboratories International (NYSE:CRL) (?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $87.17 (2.65% downside)

Analysts' Ratings History for Charles River Laboratories International (NYSE:CRL)
Show:
DateFirmActionRatingPrice TargetDetails
2/15/2017Jefferies Group LLCBoost Price TargetBuy$104.00View Rating Details
1/4/2017Evercore ISIUpgradeHold -> Buy$86.50View Rating Details
12/16/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$75.00 -> $77.00View Rating Details
11/30/2016Barclays PLCUpgradeUnderweight -> Equal Weight$65.00 -> $77.00View Rating Details
11/18/2016Bank of America CorpSet Price TargetBuy$93.00View Rating Details
9/30/2016Credit Suisse GroupReiterated RatingHold -> NeutralView Rating Details
8/4/2016Citigroup Inc.Boost Price TargetNeutral$85.00 -> $90.00View Rating Details
5/22/2016KeyCorpReiterated RatingHold$77.00View Rating Details
4/26/2016GabelliInitiated CoverageBuy$96.00View Rating Details
2/11/2016Deutsche Bank AGReiterated RatingHold$85.00 -> $82.00View Rating Details
1/8/2016Robert W. BairdBoost Price TargetOutperform$86.00 -> $92.00View Rating Details
1/7/2016Wells Fargo & CoUpgradeMarket Perform -> OutperformView Rating Details
8/28/2015William BlairReiterated RatingOutperformView Rating Details
7/10/2015Morgan StanleyReiterated RatingEqual Weight$65.00 -> $68.00View Rating Details
5/4/2015Edward JonesUpgradeNeutral -> BuyView Rating Details
5/4/2015SunTrust Banks, Inc.UpgradeNeutral -> Buy$88.00View Rating Details
4/30/2015Cantor FitzgeraldReiterated RatingBuy$78.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Charles River Laboratories International (NYSE:CRL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017        
2/14/2017Q416$1.11$1.21$441.64 million$466.80 millionViewListenView Earnings Details
11/2/2016Q316$1.13$1.18$291.20 million$425.70 millionViewListenView Earnings Details
8/3/2016Q216$1.10$1.20$425.05 million$434.10 millionViewListenView Earnings Details
5/4/2016Q116$0.90$0.98$354.92 million$354.90 millionViewListenView Earnings Details
2/10/2016Q415$0.94$1.00$349.20 million$353.90 millionViewListenView Earnings Details
11/4/2015Q315$0.94$1.03$340.09 million$349.50 millionViewListenView Earnings Details
7/30/2015Q215$0.97$0.96$338.30 million$339.60 millionViewListenView Earnings Details
4/29/2015Q115$0.82$0.79$324.00 million$320.40 millionViewListenView Earnings Details
2/10/2015Q414$0.72$0.81$318.73 million$329.50 millionViewListenView Earnings Details
10/29/2014Q314$0.80$0.86$326.70 million$327.60 millionViewListenView Earnings Details
8/6/2014Q214$0.82$0.97$327.96 million$341.18 millionViewListenView Earnings Details
4/30/2014Q114$0.74$0.82$302.08 million$299.40 millionViewListenView Earnings Details
2/12/2014Q413$0.68$0.73$289.56 million$289.20 millionViewListenView Earnings Details
10/30/2013Q313$0.70$0.79$290.28 million$292.10 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.71$0.73$293.77 million$294.40 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.71$0.69$294.53 million$291.20 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.60$0.64$280.81 million$280.10 millionViewListenView Earnings Details
10/30/2012$0.62$0.65ViewN/AView Earnings Details
8/7/2012$0.66$0.75ViewN/AView Earnings Details
5/2/2012$0.65$0.70ViewN/AView Earnings Details
2/13/2012$0.56$0.69ViewN/AView Earnings Details
11/1/2011$0.58$0.57ViewN/AView Earnings Details
8/2/2011$0.60$0.70ViewN/AView Earnings Details
5/3/2011$0.55$0.61ViewN/AView Earnings Details
2/8/2011$0.50$0.60ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Charles River Laboratories International (NYSE:CRL)
Current Year EPS Consensus Estimate: $5.06 EPS
Next Year EPS Consensus Estimate: $5.64 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20169$0.84$0.95$0.91
Q2 20166$1.09$1.13$1.11
Q3 20165$1.12$1.14$1.14
Q4 20165$1.11$1.12$1.11
Q1 20175$1.07$1.16$1.12
Q2 20175$1.24$1.30$1.28
Q3 20175$1.27$1.30$1.29
Q4 20175$1.33$1.47$1.37
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Charles River Laboratories International (NYSE:CRL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Charles River Laboratories International (NYSE:CRL)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 95.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2017James C FosterChairmanSell9,717$87.64$851,597.88View SEC Filing  
1/30/2017David P JohstInsiderSell13,950$78.00$1,088,100.00View SEC Filing  
12/2/2016Stephen D ChubbDirectorSell4,564$71.57$326,645.48View SEC Filing  
11/28/2016C Richard ReeseDirectorSell4,539$71.93$326,490.27View SEC Filing  
8/30/2016Davide MolhoInsiderSell7,877$84.10$662,455.70View SEC Filing  
8/5/2016James C FosterChairmanSell18,351$85.63$1,571,396.13View SEC Filing  
7/29/2016Richard F WallmanDirectorSell7,740$88.00$681,120.00View SEC Filing  
7/1/2016George MassaroDirectorSell3,740$83.09$310,756.60View SEC Filing  
5/24/2016John J CrowleyCAOSell1,913$85.00$162,605.00View SEC Filing  
5/13/2016Richard F WallmanDirectorSell1,970$82.32$162,170.40View SEC Filing  
5/10/2016Richard F WallmanDirectorSell11,990$84.00$1,007,160.00View SEC Filing  
5/9/2016George MassaroDirectorSell985$82.17$80,937.45View SEC Filing  
5/6/2016Richard F WallmanDirectorSell2,720$81.00$220,320.00View SEC Filing  
4/6/2016Davide MolhoVPSell30,667$80.00$2,453,360.00View SEC Filing  
3/2/2016Nancy GillettVPSell7,015$75.00$526,125.00View SEC Filing  
2/29/2016Nancy GillettVPSell3,646$73.50$267,981.00View SEC Filing  
2/25/2016David P JohstVPSell34,075$73.02$2,488,156.50View SEC Filing  
2/24/2016James C FosterCEOSell3,873$70.40$272,659.20View SEC Filing  
2/23/2016George M Milne JrDirectorSell10,440$73.02$762,328.80View SEC Filing  
2/22/2016James C FosterCEOSell9,831$73.12$718,842.72View SEC Filing  
2/12/2016C Richard ReeseDirectorSell4,228$71.48$302,217.44View SEC Filing  
2/12/2016Nancy GillettVPSell6,750$71.90$485,325.00View SEC Filing  
2/1/2016Stephen D ChubbDirectorSell2,000$74.76$149,520.00View SEC Filing  
12/17/2015George MassaroDirectorSell7,740$80.00$619,200.00View SEC Filing  
12/17/2015Thomas F. AckermaninsiderSell10,000$80.00$800,000.00View SEC Filing  
11/19/2015Thomas F. AckermaninsiderSell10,000$75.00$750,000.00View SEC Filing  
11/4/2015Thomas F. AckermaninsiderSell21,612$70.01$1,513,056.12View SEC Filing  
11/2/2015Stephen D ChubbDirectorSell2,000$66.57$133,140.00View SEC Filing  
8/17/2015Thomas F AckermanInsiderSell5,000$75.53$377,650.00View SEC Filing  
5/15/2015Thomas F AckermanCFOSell3,900$70.51$274,989.00View SEC Filing  
5/7/2015George MassaroDirectorSell1,360$70.21$95,485.60View SEC Filing  
3/3/2015Stephen D ChubbDirectorSell2,000$75.52$151,040.00View SEC Filing  
3/2/2015Deborah Turner KochevarDirectorSell2,600$76.59$199,134.00View SEC Filing  
3/2/2015James C FosterCEOSell2,036$76.93$156,629.48View SEC Filing  
3/2/2015Nancy GillettVPSell4,379$76.72$335,956.88View SEC Filing  
2/27/2015Nancy GillettVPSell2,772$76.95$213,305.40View SEC Filing  
2/25/2015James C FosterCEOSell4,621$75.96$351,011.16View SEC Filing  
2/25/2015Nancy GillettVPSell5,015$76.12$381,741.80View SEC Filing  
2/24/2015James C FosterCEOSell4,800$75.70$363,360.00View SEC Filing  
2/24/2015Jorg GellerVPSell12,061$76.17$918,686.37View SEC Filing  
2/23/2015James C FosterCEOSell8,423$76.56$644,864.88View SEC Filing  
2/23/2015Jorg GellerVPSell7,041$76.59$539,270.19View SEC Filing  
2/20/2015George M Milne JrDirectorSell6,000$75.87$455,220.00View SEC Filing  
2/19/2015James C FosterCEOSell9,671$75.00$725,325.00View SEC Filing  
2/18/2015Stephen D ChubbDirectorSell5,011$73.97$370,663.67View SEC Filing  
2/17/2015Jorg GellerVPSell14,430$73.54$1,061,182.20View SEC Filing  
2/17/2015Thomas F AckermanCFOSell4,400$73.50$323,400.00View SEC Filing  
2/13/2015Davide MolhoVPSell19,075$74.00$1,411,550.00View SEC Filing  
2/12/2015Jorg GellerVPSell8,458$73.68$623,185.44View SEC Filing  
1/26/2015Thomas F AckermanCFOSell10,000$70.00$700,000.00View SEC Filing  
1/8/2015David P JohstVPSell4,737$67.00$317,379.00View SEC Filing  
1/7/2015David P JohstVPSell26,100$65.00$1,696,500.00View SEC Filing  
12/1/2014Stephen D ChubbDirectorSell2,000$64.44$128,880.00View SEC Filing  
11/28/2014David P JohstVPSell6,982$65.34$456,203.88View SEC Filing  
11/17/2014Thomas F AckermanCFOSell10,000$63.70$637,000.00View SEC Filing  
11/14/2014Jorg GellerVPSell5,610$63.57$356,627.70View SEC Filing  
11/6/2014C Richard ReeseDirectorSell5,849$63.39$370,768.11View SEC Filing  
11/4/2014John J CrowleyCAOSell1,000$64.00$64,000.00View SEC Filing  
11/3/2014Davide MolhoVPSell16,402$64.54$1,058,585.08View SEC Filing  
11/3/2014George MassaroDirectorSell16,710$65.00$1,086,150.00View SEC Filing  
11/3/2014Thomas F AckermanCFOSell36,100$65.00$2,346,500.00View SEC Filing  
10/30/2014Nancy GillettVPSell1,069$65.00$69,485.00View SEC Filing  
10/28/2014David P JohstVPSell74,780$64.00$4,785,920.00View SEC Filing  
10/3/2014James C FosterCEOSell136,647$62.00$8,472,114.00View SEC Filing  
9/29/2014Thomas F AckermanCFOSell5,000$60.00$300,000.00View SEC Filing  
9/4/2014Davide MolhoVPSell4,900$61.34$300,566.00View SEC Filing  
9/2/2014Stephen D ChubbDirectorSell2,000$59.18$118,360.00View SEC Filing  
8/26/2014George MassaroDirectorSell10,440$60.00$626,400.00View SEC Filing  
8/18/2014Thomas F AckermanCFOSell23,156$59.25$1,371,993.00View SEC Filing  
8/12/2014Richard F WallmanDirectorSell3,240$58.20$188,568.00View SEC Filing  
6/2/2014Stephen D ChubbDirectorSell2,000$52.93$105,860.00View SEC Filing  
5/22/2014Deborah Turner KochevarDirectorSell3,100$53.30$165,230.00View SEC Filing  
5/8/2014George MassaroDirectorSell1,620$52.70$85,374.00View SEC Filing  
5/5/2014Thomas AckermanCFOSell5,430$50.76$275,626.80View SEC Filing  
3/7/2014Nancy GillettVPSell10,110$58.36$590,019.60View SEC Filing  
3/4/2014Nancy GillettVPSell13,650$58.98$805,077.00View SEC Filing  
3/3/2014Stephen ChubbDirectorSell2,000$58.70$117,400.00View SEC Filing  
2/28/2014Jorg GellerVPSell7,486$59.41$444,743.26View SEC Filing  
2/27/2014Nancy GillettVPSell4,000$60.00$240,000.00View SEC Filing  
2/25/2014Jorg GellerVPSell3,188$58.49$186,466.12View SEC Filing  
2/20/2014Nancy GillettVPSell4,000$58.96$235,840.00View SEC Filing  
2/19/2014Stephen ChubbDirectorSell5,198$58.35$303,303.30View SEC Filing  
2/18/2014Thomas AckermanCFOSell14,000$58.05$812,700.00View SEC Filing  
1/13/2014David JohstVPSell19,750$58.00$1,145,500.00View SEC Filing  
1/7/2014George MassaroDirectorSell5,750$54.00$310,500.00View SEC Filing  
12/20/2013Thomas AckermanCFOSell5,000$52.72$263,600.00View SEC Filing  
12/4/2013Jorg GellerVPSell7,200$51.93$373,896.00View SEC Filing  
12/2/2013Stephen ChubbDirectorSell2,000$51.92$103,840.00View SEC Filing  
9/16/2013George MassaroDirectorSell5,958$47.38$282,290.04View SEC Filing  
9/9/2013James C FosterCEOSell174,479$47.00$8,200,513.00View SEC Filing  
9/4/2013Thomas F AckermanCFOSell6,100$46.13$281,393.00View SEC Filing  
9/3/2013Stephen ChubbDirectorSell2,000$46.49$92,980.00View SEC Filing  
8/29/2013James FosterCEOSell40,983$47.00$1,926,201.00View SEC Filing  
8/22/2013Davide MolhoVPSell6,500$47.93$311,545.00View SEC Filing  
8/20/2013Stephen ChubbDirectorSell4,000$47.46$189,840.00View SEC Filing  
8/5/2013Jorg GellerVPSell3,025$46.38$140,299.50View SEC Filing  
8/5/2013Richard WallmanDirectorSell1,500$45.95$68,925.00View SEC Filing  
8/2/2013Davide MolhoVPSell4,100$45.89$188,149.00View SEC Filing  
8/2/2013Deborah Turner KochevarDirectorSell4,447$46.02$204,650.94View SEC Filing  
8/2/2013Thomas AckermanCFOSell26,250$46.03$1,208,287.50View SEC Filing  
6/3/2013Thomas F AckermanCFOSell4,000$42.40$169,600.00View SEC Filing  
5/14/2013James C FosterCEOSell113,810$45.00$5,121,450.00View SEC Filing  
5/10/2013George MassaroDirectorSell2,020$44.09$89,061.80View SEC Filing  
3/13/2013David P JohstVPSell17,038$45.00$766,710.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Charles River Laboratories International (NYSE:CRL)
DateHeadline
News IconMarket Scanner: Tracking Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - The Standard (NYSE:CRL)
6milestandard.com - February 22 at 9:43 PM
News IconCharles River Laboratories International Inc CRL Financial and Strategic SWOT Analysis Review [Updated: 19012017] Prices from USD $125 (NYSE:CRL)
www.bioportfolio.com - February 20 at 11:41 AM
News IconCharles River Laboratories Intl Inc Valuation – Initial Coverage $CRL (NYSE:CRL)
www.moderngraham.com - February 20 at 11:41 AM
seekingalpha.com logoAchievements To 'CRO' About - Charles River Laboratories ... - Seeking Alpha (NYSE:CRL)
seekingalpha.com - February 19 at 4:11 PM
finance.yahoo.com logoCHARLES RIVER LABORATORIES INTERNATIONAL INC Financials (NYSE:CRL)
finance.yahoo.com - February 18 at 4:18 PM
News IconMarket Update: Watching Shares of Charles River Laboratories International Inc. (CRL) - Providence Standard (NYSE:CRL)
providencestandard.com - February 16 at 4:35 PM
News IconTechnical Updates for Charles River Laboratories International Inc. (CRL) - Midway Monitor (NYSE:CRL)
midwaymonitor.com - February 16 at 4:35 PM
News IconInvestor Corner: Checking the Numbers on Charles River Laboratories International, Inc. (NYSE:CRL) - The Standard (NYSE:CRL)
6milestandard.com - February 16 at 4:35 PM
News IconAnalyst's Proposition on Brandywine Realty Trust (BDN), Charles River Laboratories International, Inc. (CRL) - The USA Commerce (NYSE:CRL)
www.theusacommerce.com - February 16 at 4:35 PM
News IconCharles River Laboratories International, Inc. (CRL): An Examination Of The Chart For Today's Session - NY Stock News (NYSE:CRL)
nystocknews.com - February 16 at 4:35 PM
capitalcube.com logoCharles River Laboratories International, Inc. :CRL-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 (NYSE:CRL)
www.capitalcube.com - February 16 at 4:35 PM
News IconCharles River splits off and divests CDMO business (NYSE:CRL)
www.outsourcing-pharma.com - February 16 at 12:07 PM
4-traders.com logoCHARLES RIVER LABORATORIES INTERNATIONAL, INC. (NYSE:BRK.A) Files An 8-K Results of Operations and Financial Condition (NYSE:CRL)
www.4-traders.com - February 16 at 12:07 PM
capitalcube.com logoCharles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 (NYSE:CRL)
www.capitalcube.com - February 16 at 12:07 PM
reuters.com logoBRIEF-Charles River Laboratories reports Q4 GAAP earnings per share $0.93 (NYSE:CRL)
www.reuters.com - February 14 at 10:24 PM
News IconWhy Charles River Laboratories International Inc’s (CRL) ROE Of 17.7% Does Not Tell The Whole Story (NYSE:CRL)
simplywall.st - February 14 at 10:24 PM
finance.yahoo.com logoEdited Transcript of CRL earnings conference call or presentation 14-Feb-17 1:00pm GMT (NYSE:CRL)
finance.yahoo.com - February 14 at 10:24 PM
nasdaq.com logoEarnings Reaction History: Charles River Laboratories, 40.0% Follow-Through Indicator, 4.0% Sensitive (NYSE:CRL)
www.nasdaq.com - February 14 at 5:22 PM
4-traders.com logoCharles River Laboratories Intl : tops Street 4Q forecasts (NYSE:CRL)
www.4-traders.com - February 14 at 5:22 PM
rttnews.com logoCharles River Laboratories International Inc. Reveals 23% Rise In Q4 Earnings (NYSE:CRL)
www.rttnews.com - February 14 at 5:22 PM
seekingalpha.com logoCharles River Laboratories International (CRL) Q4 2016 Results - Earnings Call Transcript (NYSE:CRL)
seekingalpha.com - February 14 at 5:22 PM
us.rd.yahoo.com logoCharles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance (NYSE:CRL)
us.rd.yahoo.com - February 14 at 5:22 PM
us.rd.yahoo.com logo6:36 am Charles River beats by $0.10, beats on revs; guides FY17 EPS in-line, revs below consensus; divests contract development & manufacturing biz for $75 mln (NYSE:CRL)
us.rd.yahoo.com - February 14 at 5:22 PM
sg.finance.yahoo.com logoCharles River tops Street 4Q forecasts (NYSE:CRL)
sg.finance.yahoo.com - February 14 at 5:22 PM
biz.yahoo.com logoCHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Finan (NYSE:CRL)
biz.yahoo.com - February 14 at 5:22 PM
biz.yahoo.com logoQ4 2016 Charles River Laboratories International Inc Earnings Release - Before Market Open (NYSE:CRL)
biz.yahoo.com - February 14 at 5:22 PM
biz.yahoo.com logoCharles River Laboratories International Inc Earnings Call scheduled for 8:00 am ET today (NYSE:CRL)
biz.yahoo.com - February 14 at 5:22 PM
News IconStock Focus: Looking at Levels for Charles River Laboratories International, Inc. (NYSE:CRL) - Searcy News (NYSE:CRL)
searcysentinel.com - February 14 at 3:13 AM
News IconCompany Watch for Charles River Laboratories International, Inc. (NYSE:CRL) - Piedmont Register (NYSE:CRL)
piedmontregister.com - February 14 at 3:13 AM
finance.yahoo.com logoHealthcare Stock Q4 Earnings Slated for Feb 14: ESRX, CRL, Q (NYSE:CRL)
finance.yahoo.com - February 13 at 5:09 PM
businesswire.com logoCharles River Laboratories Changes Time of Fourth-Quarter 2016 Earnings and 2017 Guidance Conference Call - Business Wire (press release) (NYSE:CRL)
www.businesswire.com - February 9 at 9:54 PM
finance.yahoo.com logoCharles River Laboratories Changes Time of Fourth-Quarter 2016 Earnings and 2017 Guidance Conference Call (NYSE:CRL)
finance.yahoo.com - February 9 at 4:54 PM
live-pr.com logo"Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report" Published (NYSE:CRL)
www.live-pr.com - February 2 at 4:53 PM
News IconAnalysts Take: Charles River Laboratories International, Inc. (NYSE:CRL) Projected Earnings & Price Targets - Aiken Advocate (NYSE:CRL)
aikenadvocate.com - February 1 at 4:51 PM
nasdaq.com logoCRL Crosses Above Key Moving Average Level (NYSE:CRL)
www.nasdaq.com - January 31 at 5:03 PM
finance.yahoo.com logoCharles River Laboratories Announces Progress Update for Collaboration with Moderna Therapeutics (NYSE:CRL)
finance.yahoo.com - January 30 at 8:41 AM
News IconAre Analysts Predicting a Near-Term Upswing For Charles River Laboratories International, Inc. (NYSE:CRL)? - Wall Street Beacon (NYSE:CRL)
wsbeacon.com - January 29 at 4:36 PM
News IconStock Review: Checking in on Share of Charles River Laboratories International, Inc. (NYSE:CRL) - The Tribune (NYSE:CRL)
lakecitytribune.com - January 26 at 10:40 PM
News IconTechnical Update on Shares of Charles River Laboratories International Inc. (CRL) - Springdale Times (NYSE:CRL)
springdaletimes.com - January 26 at 5:39 PM
247wallst.com logoDespite Pharma Risks, Jefferies Likes 4 Top Contract Research ... - 24/7 Wall St. (NYSE:CRL)
247wallst.com - January 25 at 3:08 AM
News IconLarge Inflow of Money Witnessed in Charles River Laboratories ... - Highland Mirror (NYSE:CRL)
www.highlandmirror.com - January 25 at 3:08 AM
News IconEarnings in Full Force, Analysts Take Aim at Charles River Laboratories International, Inc. (NYSE:CRL) - Wall Street Beacon (NYSE:CRL)
wsbeacon.com - January 24 at 2:48 AM
News IconWhat The Charts Are Saying About Charles River Laboratories International, Inc. (NYSE:CRL) - The Tribune (NYSE:CRL)
lakecitytribune.com - January 23 at 9:48 PM
finance.yahoo.com logoJohn Rogers Comments on Charles River Laboratories Intl (NYSE:CRL)
finance.yahoo.com - January 20 at 5:42 PM
News IconWill The Needle Move For Charles River Laboratories International, Inc. (NYSE:CRL) Shares This Earnings Season? - Wall Street Beacon (NYSE:CRL)
wsbeacon.com - January 19 at 10:47 PM
News IconInvestor Notebook: Focusing in on Shares of Charles River Laboratories International Inc. (CRL) - Springdale Times (NYSE:CRL)
springdaletimes.com - January 19 at 10:47 PM
businesswire.com logoCharles River Laboratories Schedules Fourth-Quarter 2016 Earnings and 2017 Guidance Release and Conference Call - Business Wire (press release) (NYSE:CRL)
www.businesswire.com - January 19 at 10:47 PM
bizjournals.com logoResearch Reports Initiation on Healthcare Stocks -- PAREXEL, Charles River Laboratories, PRA Health Sciences, and Invitae (NYSE:CRL)
www.bizjournals.com - January 19 at 5:46 PM
4-traders.com logoCharles River Laboratories Intl : Schedules Fourth-Quarter 2016 Earnings and 2017 Guidance Release and Conference Call (NYSE:CRL)
www.4-traders.com - January 19 at 5:46 PM
finance.yahoo.com logoCharles River Laboratories Schedules Fourth-Quarter 2016 Earnings and 2017 Guidance Release and Conference Call (NYSE:CRL)
finance.yahoo.com - January 19 at 5:46 PM

Social

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Where is Charles River Laboratories International's stock going? Where will Charles River Laboratories International's stock price be in 2017?

9 analysts have issued 1-year price objectives for Charles River Laboratories International's stock. Their predictions range from $77.00 to $104.00. On average, they anticipate Charles River Laboratories International's share price to reach $87.17 in the next twelve months.

When will Charles River Laboratories International announce their earnings?

Charles River Laboratories International is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

What are analysts saying about Charles River Laboratories International stock?

Here are some recent quotes from research analysts about Charles River Laboratories International stock:

  • Jefferies Group LLC analysts commented, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments. Guidance bracketed consensus, lower than us (as expected). We point to margin expansion (with continued price) and capital deployment as upside sources. Strong Discovery and Early Development demand (see our research pointing to funding shifts to Early Dev) should support high single digit organic growth." (2/15/2017)
  • According to Zacks Investment Research, "Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years. " (11/4/2016)

Who owns Charles River Laboratories International stock?

Charles River Laboratories International's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (3.76%), State Street Corp (2.59%), AQR Capital Management LLC (2.37%), Renaissance Technologies LLC (2.37%), Alyeska Investment Group L.P. (1.79%) and Brown Advisory Inc. (1.49%). Company insiders that own Charles River Laboratories International stock include C Richard Reese, David P Johst, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, John J Crowley, Nancy Gillett, Richard F Wallman, Stephen D Chubb and Thomas F Ackerman.

Who sold Charles River Laboratories International stock? Who is selling Charles River Laboratories International stock?

Charles River Laboratories International's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Numeric Investors LLC, Guggenheim Capital LLC, Federated Investors Inc. PA, Century Capital Management LLC, Hodges Capital Management Inc., State Street Corp and Janus Capital Management LLC. Company insiders that have sold Charles River Laboratories International stock in the last year include C Richard Reese, David P Johst, Davide Molho, George Massaro, James C Foster, John J Crowley, Nancy Gillett, Richard F Wallman and Stephen D Chubb.

Who bought Charles River Laboratories International stock? Who is buying Charles River Laboratories International stock?

Charles River Laboratories International's stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Assenagon Asset Management S.A., Russell Investments Group Ltd., Alyeska Investment Group L.P., Allianz Asset Management AG, Renaissance Technologies LLC, Brown Advisory Inc. and Two Sigma Investments LP.

How do I buy Charles River Laboratories International stock?

Shares of Charles River Laboratories International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Charles River Laboratories International stock cost?

One share of Charles River Laboratories International stock can currently be purchased for approximately $89.54.

Charles River Laboratories International (NYSE:CRL) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Earnings History Chart

Earnings by Quarter for Charles River Laboratories International (NYSE:CRL)

Dividend History Chart

Dividend Payments by Quarter for Charles River Laboratories International (NYSE:CRL)

Last Updated on 2/27/2017 by MarketBeat.com Staff